Dr Prateek Srivastava

Profile Summary

Dr Prateek Srivastava successfully completed his PhD from Department of Chemistry, BANARAS HINDU UNIVERSITY, Varanasi, India

His Specialization is in synthesis and characterization of the Mesoporous Silica Nanomaterial (MCM-41 and SBA-15) and its application in cancer treatment.

He then moved to BEN GURION UNIVERSITY ,Israel for further po

Dr Prateek Srivastava successfully completed his PhD from Department of Chemistry, BANARAS HINDU UNIVERSITY, Varanasi, India

His Specialization is in synthesis and characterization of the Mesoporous Silica Nanomaterial (MCM-41 and SBA-15) and its application in cancer treatment.

He then moved to BEN GURION UNIVERSITY ,Israel for further post-doctoral studies.

He has achieved a number of noteworthy international publications, a few of which are listed below.

Show Less

Research Paper References

Research Paper-1

Title: Dendritic cell-targeted nanoparticles enhance T cell activation and anti-tumor immune responses by boosting antigen presentation and blocking PD-L1 pathways. Prateek Srivastava, Marie Rtter, Gover Antoniraj, Yvonne Ventura, Ayelet David, ACS Appl. Mater. Interfaces 2024, 16, 40, 53577–53590 2024.

Research Paper-2

Prateek Srivastava, Sumit Kumar Hira, Uttam Gupta, Vivek Kumar Singh, Ranjeet Singh, Pankaj Pandey, Divesh Narayan Srivastava, Ram Adhar Singh and Partha Pratim Manna, Pepsin Assisted Doxorubicin Delivery from Mesoporous Silica Nanoparticles Downsizes Solid Tumor Volume and Enhances Therapeutic Efficacy in Experimental Murine Lymphoma, ACS Applied Bio Materials 2018 1 (6), 2133-2140

Research Paper-3

Prateek Srivastava, Sumit Kumar Hira, Divesh Narayan Srivastava, Vivek Kumar Singh, Uttam Gupta, Ranjeet Singh, Ram Adhar Singh, and Partha Pratim Manna, ATP-Decorated Mesoporous Silica for Biomineralization of Calcium Carbonate and P2 Purinergic Receptor- Mediated Antitumor Activity against Aggressive Lymphoma, ACS Appl. Mater. Interfaces 2018, 10, 6917−6929.

Research Paper-4

Prateek Srivastava, Sumit Kumar Hira, Amod Sharma, Mohammad Kashif, Prashant Srivastava, Divesh Narayan Srivastava, Ram Adhar Singh, and Partha Pratim Manna, Telomerase Responsive Delivery of Doxorubicin from Mesoporous Silica Nanoparticles in Multiple Malignancies: Therapeutic Efficacies against Experimental Aggressive Murine Lymphoma, ACS Bioconjugate Chem. 2018, 29, 2107−2119.

Research Paper-5

Prateek Srivastava, Sumit Kumar Hira, Divesh Narayan Srivastava, Uttam Gupta, Pradip Sen, Ram Adhar Singh, and Partha Pratim Manna, Protease-Responsive Targeted Delivery of Doxorubicin from Bilirubin-BSA-Capped Mesoporous Silica Nanoparticles against Colon Cancer, ACS Biomater. Sci. Eng. 2017, 3, 3376−3385

Research Paper-6

Prateek srivastava, Sumit Hira, Ankush Paladhi, Ranjeet Singh, Uttam gupta, Divesh Narayan Srivastava, , Ram Adhar Singh, and Partha Pratim Manna, Studies on Interaction Potency Model based Drug Synergy and Therapeutic Potential of Triple Stimuli Responsive Delivery of Doxorubicin and 5-Fluoro-2-Deoxyuridine against Lymphoma using Disulfide Bridged Cysteine over Mesoporous Silica Nanoparticles, RSC, Journal of materials chemistry B , 2020,8, 1411-1421.

Research Paper-7

Prateek Srivastava, Sumit Hira, Ankush Paladhi, Ranjeet Singh, Uttam gupta, Divesh Narayan Srivastava, , Ram Adhar Singh, and Partha Pratim Manna, Targeting PD-1 in CD8+ T cells by Biomimetic Bilirubin-5-Fluoro-2-deoxyuridine-BSA Nanoconstruct for Effective Chemotherapy against Experimental Lymphoma, ACS Molecular Pharmaceutics 2021, 18, 5, 2053–2065.

Research Paper-8

Book Chapter- Book entitled "2D Nanomaterials for Energy and Environmental Sustainability (Series: Materials Horizons: From Nature to Nanomaterials)" published on 02.03.2022 (publishing officer SPRINGER NATURE).

For More papers visit

Go to Linkedin Profile